Selpercatinib(LuciSel)

On May 8, 2020, Selpercatinib, as a prescription drug targeting the RET protein, was the first to be approved by the U.S. Food and Drug Administration (FDA). Use only as directed by a physician.

Lucius Related Certificates

Drug Test Report

Drug Approval Certificate

Target of Action

RET protein

Dosage and Administration

The dosage of selpercatinib should be adjusted according to the patient’s actual condition. For specific details, please consult a doctor and strictly follow medical advice.

Recommended Reading: Dosage and Administration of Selpercatinib (Retevmo)

Side Effects

Common side effects: Diarrhea, fatigue, dry mouth, etc.

Serious side effects: Liver problems, lung problems, hypertension, etc.

Reference Article: Side Effects of Selpercatinib (Retevmo)

Use in Special Populations

Pregnancy:

Your doctor will perform a pregnancy test before you start treatment with selpercatinib.

You should use effective contraception during treatment and for 1 week after the last dose of selpercatinib.

Lactation:

It is not known whether selpercatinib passes into breast milk.

Do not breastfeed during treatment with selpercatinib and for 1 week after the last dose.

Daily Precautions

1. Patients should be informed that hepatotoxicity may occur. If any signs or symptoms related to hepatotoxicity appear, contact a healthcare professional immediately.

2. Patients should be informed that blood pressure needs to be monitored regularly. If symptoms of elevated blood pressure or high measurements occur, contact a healthcare professional.

3. Patients should be informed that selpercatinib may cause QT interval prolongation. If any symptoms related to QT interval prolongation (such as syncope) occur, inform a healthcare professional.

from FDA，2024.06